Diazepam (Valtoco) vs Midazolam (Nayzilam)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: GABA-A receptor · full Epilepsy pipeline

Diazepam (Valtoco)

Marketed by Neurelis, Inc.

Approved in Epilepsysmall molecule
Weak signal

NCT02721069 · Phase 3 · completed

The study was open-label, nonrandomized, and had no placebo or active comparator, so it provides uncontrolled safety and treatment-exposure information rather than comparative evidence of effectiveness. Its primary endpoint was the number of participants receiving NRL-1 over 12 months, not a hard clinical seizure outcome, and no formal primary-endpoint comparison was applicable.

Next expected readout: December 2026 · NCT06346262 (registry estimate)

Reported efficacy

Number of Participants Who Received NRL-1 (Valtoco) (12 months): Number of Participants Who Received NRL-1 (Valtoco) (12 months): NRL-1 5mg 9 Participants | NRL-1 10mg 54 Participants | NRL-1 15 mg 46 Participants | NRL-1 20mg 54 Participants (not_applicable)

Result source: NCT02721069

Midazolam (Nayzilam)

Marketed by UCB

Approved in Epilepsysmall molecule
Reliable signal

NCT01390220 · Phase 3 · terminated

This was a randomized, triple-blind, placebo-controlled trial in 201 patients, and the primary outcome, control of a seizure cluster with no recurrence, was reached significantly more often with midazolam than with placebo (72 of 134 patients vs 23 of 67, p=0.011).

Reported efficacy

Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67 (met)

Result source: NCT01390220

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDiazepam (Valtoco)Midazolam (Nayzilam)
Seizure frequency, % change—Not reported—Not reported
50% responder rate—Not reported—Not reported
Seizure freedom—Not reported54.8% vs 38.7%+16.1 vs placebowk 0.04 · n 31NCT01999777

Seizure frequency, % change

Diazepam (Valtoco)
—Not reported
Midazolam (Nayzilam)
—Not reported

50% responder rate

Diazepam (Valtoco)
—Not reported
Midazolam (Nayzilam)
—Not reported

Seizure freedom

Diazepam (Valtoco)
—Not reported
Midazolam (Nayzilam)
54.8% vs 38.7%+16.1 vs placebowk 0.04 · n 31NCT01999777
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Diazepam (Valtoco): 3 of 4 rows · Midazolam (Nayzilam): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDiazepam (Valtoco)Midazolam (Nayzilam)
Dropout rate
—20mga
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
show 4 more results
—15mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
—10mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
—5mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
5.3%
NCT02724423 · Phase 1 · registry result, not featured evidence
—5 mg + 5 mga
NCT01390220 · Phase 3 · Epilepsy · phase 3
show 4 more results
—5 mg only
NCT01390220 · Phase 3 · Epilepsy · phase 3
—USL261 CP
NCT01390220 · Phase 3 · Epilepsy · phase 3
31.2%USL261 TDP
NCT01390220 · Phase 3 · Epilepsy · phase 3
0%
NCT01999777 · Phase 3 · monotherapy
Discontinued due to AEs
—20mga
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
show 4 more results
—15mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
—10mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
—5mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
—
NCT02724423 · Phase 1 · registry result, not featured evidence
—5 mg + 5 mga
NCT01390220 · Phase 3 · Epilepsy · phase 3
show 4 more results
—5 mg only
NCT01390220 · Phase 3 · Epilepsy · phase 3
—USL261 CP
NCT01390220 · Phase 3 · Epilepsy · phase 3
5.8%USL261 TDP
NCT01390220 · Phase 3 · Epilepsy · phase 3
—
NCT01999777 · Phase 3 · monotherapy
Serious AEs
24.1%20mga
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
show 4 more results
32.6%15mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
37%10mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
22.2%5mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
1.8%
NCT02724423 · Phase 1 · registry result, not featured evidence
0%5 mg + 5 mga
NCT01390220 · Phase 3 · Epilepsy · phase 3
show 4 more results
0%5 mg only
NCT01390220 · Phase 3 · Epilepsy · phase 3
—USL261 CP
NCT01390220 · Phase 3 · Epilepsy · phase 3
0.7%USL261 TDP
NCT01390220 · Phase 3 · Epilepsy · phase 3
0%
NCT01999777 · Phase 3 · monotherapy
Most frequent reported AEs
20mga
nasal discomfort 11.1%
nasopharyngitis 7.4%
upper respiratory tract infection 7.4%
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
show 4 more results
15mg
seizure 15.2%
upper respiratory tract infection 15.2%
nasal discomfort 8.7%
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
10mg
nasopharyngitis 22.2%
pyrexia 18.5%
upper respiratory tract infection 16.7%
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
5mg
influenza 33.3%
diarrhoea 22.2%
nasopharyngitis 11.1%
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
dysgeusia 5.3%
nasal discomfort 3.5%
nasopharyngitis 3.5%
NCT02724423 · Phase 1 · registry result, not featured evidence
5 mg + 5 mga
nasal discomfort 16.3% (placebo 7.3%)
somnolence 9.3% (placebo 9.8%)
throat irritation 7% (placebo 2.4%)
NCT01390220 · Phase 3 · Epilepsy · phase 3
show 3 more results
5 mg only
somnolence 9.9% (placebo 9.8%)
headache 6.6% (placebo 0%)
nasal discomfort 5.5% (placebo 7.3%)
NCT01390220 · Phase 3 · Epilepsy · phase 3
nasal discomfort 16.1% (placebo 7.3%)
somnolence 9.6% (placebo 9.8%)
lacrimation increased 6.8% (placebo 2.4%)
NCT01390220 · Phase 3 · Epilepsy · phase 3
nasal discomfort 16.1% (placebo 16.1%)
nausea 9.7% (placebo 3.2%)
throat irritation 9.7% (placebo 9.7%)
NCT01999777 · Phase 3 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Midazolam (Nayzilam)

Seizure Cluster Treatment Success 53.7% (n=134) vs 34.3% (n=67) placebo
event count · % of participants
NCT01390220 · Phase 3 · Epilepsy · phase 3 · converted to % from 72 Participants as posted
Seizure Recurrence 4h 38.1% (n=134) vs 59.7% (n=67) placebo
event count · % of participants
NCT01390220 · Phase 3 · Epilepsy · phase 3 · converted to % from 51 Participants as posted
Seizure Recurrence 24 h 37.3% (n=134) vs 46.3% (n=67) placebo
event count · % of participants
NCT01390220 · Phase 3 · Epilepsy · phase 3 · converted to % from 50 Participants as posted
Time to Next Seizure NA vs 12.1 placebo hours
absolute value · hours
NCT01390220 · Phase 3 · Epilepsy · phase 3
Seizure-free 54.8% (n=31) vs 38.7% (n=31) placebo @ 0.04wk
responder rate · % of participants
NCT01999777 · Phase 3 · monotherapy · converted to % from 17 Participants as posted
Time to First Seizure NA vs 3.9 placebo hours
absolute value · hours
NCT01999777 · Phase 3 · monotherapy

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Diazepam (Valtoco)'s landscape · Midazolam (Nayzilam)'s landscape